NCT06508606View on ClinicalTrials.gov

AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

AK117

AK117: 45mg/kg (D1, IVGTT, Q3W maintained for one year or until progression or intolerable toxicity occurred

DRUG

anti-EGFR

anti-EGFR:initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained for one year or until progression or intolerable toxicity occurred

All Listed Sponsors
lead

West China Hospital

OTHER